1,494.00
-13(-0.86%)
Currency In JPY
Address
6, Kanda Surugadai 4-Chome
Tokyo, 101-8311
Japan
Phone
81 3 3525 4700
Website
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
2042
First IPO Date
January 04, 2001
| Name | Title | Pay | Year Born |
| Mr. Yutaka Ogihara | President, Chief Executive Officer & Chairman | 0 | 1967 |
| Katsuhiro Hamada | Executive Officer & GM of Reliability Assurance Headquarters | 0 | N/A |
| Dr. Makoto Yanai Ph.D. | Executive Officer & Deputy GM of Business Development Division | 0 | N/A |
| Mr. Michiro Onota | Executive Director & CMO | 0 | 1960 |
| Noriaki Tamura | Executive Officer, Chief Commercial Officer & GM of Pharmaceutical Sales Division | 0 | N/A |
| Kimiya Masada | Corporate Officer & Director of Product Strategy | 0 | N/A |
| Takaaki Kaji | Executive Officer & Chief Business Development Officer | 0 | N/A |
| Kiyoo Uehara | Executive Officer, Chief Human Resource Officer & Director of General Affairs | 0 | N/A |
| Yasuji Kurose | Chief Financial Officer, CStO, Director of Corporate Planning & Executive Director | 0 | N/A |
| Junichi Ishiyama | Executive Officer, Chief Scientific Officer & GM of Drug Discovery Division | 0 | N/A |
KYORIN Holdings, Inc., through its subsidiaries, researches and develops, produces, and sells ethical and generic drugs in Japan and internationally. The company offers Flutiform, a drug for the treatment of asthma; Desalex, an antiallergic agent; Beova, Uritos, and Imidafenacin KYORIN therapeutic agents for overactive bladder; Lasvic, a quinolone synthetic antibacterial agent; Pentasa, a remedy for ulcerative colitis/Crohn's disease; Nasonex, an allergic rhinitis therapeutic agent; and Kipres, a leukotriene receptor antagonist anti-bronchial asthma and allergic rhinitis drug. It also provides Mucodyne, a mucoregulating drug; Montelukast KM, a drug for the treatment of bronchial asthma and allergic rhinitis; GeneSoC, a real-time PCR system; Rubysta, a disinfectant cleaner; Milton, a disinfectant; over-the-counter drugs; prescription medicines and quasi-drugs, diagnostics, and industrial chemicals; and reagents and intermediates. In addition, the company offers subcontracted drug manufacturing services. Further, it is involved in the discovery and evaluation of candidate compounds; and research and analysis of other companies' technologies and collection of information concerning clinical trial. KYORIN Holdings, Inc. was founded in 1923 and is based in Tokyo, Japan.